FULGENT GENETICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
FULGENT GENETICS, INC. (FLGT) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$14.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-07-30
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$11.90M, a 328.64% decline year-over-year.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.12M.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $12.32M, a 1862.58% increase year-over-year.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$1.13M.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $8.91M.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$3.96M, a 245.73% decline from fiscal 2023.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $2.72M.
- FULGENT GENETICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$10.91M, a 183.44% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$14.02M 10-Q · filed 2026-07-30 | -$1.69M derived: sum of 3 quarters · filed 2026-07-30 | -$2.83M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | -$2.12M 10-Q · filed 2026-05-01 | $10.20M derived: sum of 2 quarters · filed 2026-05-01 | $9.07M derived: sum of 3 quarters · filed 2026-05-01 | $14.27M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $11.19M derived: sum of 2 quarters · filed 2026-02-27 | $16.40M derived: sum of 3 quarters · filed 2026-07-30 | $8.91M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.07M derived: sum of 2 quarters · filed 2026-07-30 | -$3.41M 10-Q · filed 2025-11-07 | -$2.79M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.28M 10-Q · filed 2026-07-30 | -$1.65M derived: sum of 3 quarters · filed 2026-07-30 | -$3.48M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | -$7.49M 10-Q · filed 2026-05-01 | -$6.86M derived: sum of 2 quarters · filed 2026-05-01 | -$8.68M derived: sum of 3 quarters · filed 2026-05-01 | -$7.06M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | $628.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$1.20M derived: sum of 2 quarters · filed 2026-02-27 | $424.00K derived: sum of 3 quarters · filed 2026-02-27 | -$3.96M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$204.00K derived: sum of 2 quarters · filed 2025-11-07 | -$4.59M 10-Q · filed 2025-11-07 | $5.83M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$2.76M 10-Q · filed 2025-08-01 | $7.65M derived: sum of 3 quarters · filed 2026-02-27 | $7.47M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | -$4.38M 10-Q · filed 2025-05-02 | $51.00K 10-Q · filed 2024-05-03 | $6.03M derived: sum of 2 quarters · filed 2026-02-27 | $5.85M derived: sum of 3 quarters · filed 2026-02-27 | $7.45M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2023-12-31 | $10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.24M derived: sum of 2 quarters · filed 2026-02-27 | $11.83M derived: sum of 3 quarters · filed 2026-02-27 | $2.72M 10-K · filed 2026-02-27 | $14.21M 10-K · filed 2024-02-28 | |||
| 2023-09-30 | -$177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $1.42M derived: sum of 2 quarters · filed 2024-11-08 | -$7.70M 10-Q · filed 2024-11-08 | -$323.00K 10-Q · filed 2023-11-03 | -$5.71M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$7.52M 10-Q · filed 2024-08-02 | -$4.52M 10-Q · filed 2023-08-04 | -$5.53M derived: sum of 3 quarters · filed 2025-02-28 | -$18.70M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-03-31 | -$9.11M 10-Q · filed 2024-05-03 | -$7.12M derived: sum of 2 quarters · filed 2025-02-28 | -$20.29M derived: sum of 3 quarters · filed 2025-02-28 | -$11.80M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$11.18M derived: sum of 2 quarters · filed 2025-02-28 | -$2.68M derived: sum of 3 quarters · filed 2025-02-28 | -$10.91M 10-K · filed 2025-02-28 | -$31.30M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | -$13.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$4.67M derived: sum of 2 quarters · filed 2023-11-03 | -$12.90M 10-Q · filed 2023-11-03 | -$21.08M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $8.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $264.00K 10-Q · filed 2023-08-04 | -$7.91M derived: sum of 3 quarters · filed 2024-02-28 | -$14.80M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | -$8.23M 10-Q · filed 2023-05-05 | -$16.40M derived: sum of 2 quarters · filed 2024-02-28 | -$23.29M derived: sum of 3 quarters · filed 2024-02-28 | -$3.27M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | -$8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$15.06M derived: sum of 2 quarters · filed 2024-02-28 | $4.96M derived: sum of 3 quarters · filed 2024-02-28 | $13.08M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | -$6.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $13.13M derived: sum of 2 quarters · filed 2022-11-07 | $21.25M 10-Q · filed 2022-11-07 | -$953.00K 10-Q · filed 2021-11-09 | $31.74M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $20.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $28.14M 10-Q · filed 2022-08-04 | $3.08M 10-Q · filed 2021-08-10 | $38.63M derived: sum of 3 quarters · filed 2023-02-28 | $60.13M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $8.12M 10-Q · filed 2022-05-05 | $18.61M derived: sum of 2 quarters · filed 2023-02-28 | $40.11M derived: sum of 3 quarters · filed 2023-02-28 | $40.51M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $10.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $31.98M derived: sum of 2 quarters · filed 2023-02-28 | $32.39M derived: sum of 3 quarters · filed 2023-02-28 | $32.66M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $21.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $21.90M derived: sum of 2 quarters · filed 2021-11-09 | $22.17M 10-Q · filed 2021-11-09 | $22.23M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $402.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $670.00K 10-Q · filed 2021-08-10 | $732.00K derived: sum of 3 quarters · filed 2022-02-28 | $954.00K derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $268.00K 10-Q · filed 2020-05-06 | $330.00K derived: sum of 2 quarters · filed 2022-02-28 | $552.00K derived: sum of 3 quarters · filed 2022-02-28 | $539.00K derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $284.00K derived: sum of 2 quarters · filed 2022-02-28 | $271.00K derived: sum of 3 quarters · filed 2022-02-28 | $264.00K 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $209.00K derived: sum of 2 quarters · filed 2020-11-09 | $202.00K 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$20.00K 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | -$7.00K 10-Q · filed 2020-05-06 | |||||||
| 2018-12-31 | $533.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |